A detailed history of Caxton Corp transactions in Rezolute, Inc. stock. As of the latest transaction made, Caxton Corp holds 1,318,967 shares of RZLT stock, worth $6.73 Million. This represents 27.47% of its overall portfolio holdings.

Number of Shares
1,318,967
Previous 1,318,967 -0.0%
Holding current value
$6.73 Million
Previous $5.67 Million 12.78%
% of portfolio
27.47%
Previous 30.31%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$1.75 - $2.33 $147,332 - $196,162
-84,190 Reduced 6.0%
1,318,967 $2.61 Million
Q2 2022

Aug 15, 2022

BUY
$2.6 - $3.85 $545,178 - $807,283
209,684 Added 17.57%
1,403,157 $4.53 Million
Q4 2021

Feb 14, 2022

BUY
$4.21 - $7.61 $3.24 Million - $5.85 Million
769,230 Added 181.32%
1,193,473 $5.71 Million
Q4 2020

Feb 16, 2021

BUY
$11.99 - $24.05 $5.09 Million - $10.2 Million
424,243 New
424,243 $5.09 Million

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $198M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Caxton Corp Portfolio

Follow Caxton Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Corp with notifications on news.